Thursday, August 30, 2012
Coronado Biosciences Inc., of Burlington, Mass., closed a $15 million secured loan facility with Hercules Technology Growth Capital Inc. Proceeds will support Coronado's clinical programs for Trichuris suis ova (CNDO-201), a biologic therapy for autoimmune disease, and CNDO-109, a biologic therapy for acute myeloid leukemia and solid tumors.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.